Koike Fumiko, Satoh Jun-ichi, Miyake Sachiko, Yamamoto Toshiyuki, Kawai Mitsuru, Kikuchi Seiji, Nomura Kyouichi, Yokoyama Kazumasa, Ota Kohei, Kanda Takashi, Fukazawa Toshiyuki, Yamamura Takashi
Department of Immunology, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Tokyo 187-8502, Kodaira, Japan.
J Neuroimmunol. 2003 Jun;139(1-2):109-18. doi: 10.1016/s0165-5728(03)00155-3.
The molecular mechanisms for the interferon beta (IFNbeta) treatment of multiple sclerosis (MS) remain to be characterized. Using cDNA microarray technology, we have compared the gene expression profile of T and non-T cells derived from relapsing-remitting MS before and after treatment with IFNbeta-1b. IFNbeta treatment significantly altered expression of 21 genes out of 1263 at 3 and 6 months after treatment. These genes included nine with IFN-responsive promoter elements. Whereas there was no change in Th1 or Th2 marker genes, some of the changes were unexpected but coincided with the beneficial effect of IFNbeta in MS.
干扰素β（IFNβ）治疗多发性硬化症（MS）的分子机制仍有待阐明。我们利用cDNA微阵列技术，比较了复发缓解型MS患者在接受IFNβ-1b治疗前后T细胞和非T细胞的基因表达谱。IFNβ治疗在治疗后3个月和6个月时，显著改变了1263个基因中的21个基因的表达。这些基因包括9个具有IFN反应性启动子元件的基因。虽然Th1或Th2标记基因没有变化，但有些变化出乎意料，但与IFNβ对MS的有益作用相符。
